Overview

Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

Status:
Completed
Trial end date:
2016-11-11
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Ono Pharmaceutical Co. Ltd
Treatments:
Nivolumab
Criteria
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Subjects with previously treated advanced malignant solid tumor

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

- For certain subjects, willing and able to provide pre-treatment tumor sample

Exclusion Criteria:

- Known or suspected central nervous system metastases or central nervous system as the
only source of disease

- Other concomitant malignancies (with some exceptions per protocol)

- Active, known or suspected autoimmune disease